{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:57:55Z","timestamp":1784746675895,"version":"3.55.0"},"reference-count":95,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Inflammatory bowel diseases (IBD) are chronic and recurrent conditions of the gastrointestinal tract. IBD is often challenging to manage due to the complex etiology and involvement of multiple dysregulated immune pathways. Current treatments, including biologics and immunosuppressants, are associated with significant risks and side effects, highlighting the need for safer alternatives. Human milk oligosaccharides (HMOs), a group of bioactive carbohydrates found in human breast milk, play a crucial role in shaping the infant gut microbiome, modulating microbial metabolism and immune responses, and reducing inflammation. Notably, HMOs have no nutritional value for the infant and travel undigested through the upper gastrointestinal tract, serving as selective substrates for beneficial gut bacteria and supporting intestinal epithelial health. Among these, 2\u2032-fucosyllactose (2\u2032-FL) is the most abundant and well-studied HMO, functioning as a trisaccharide prebiotic. Emerging evidence suggests that the benefits of HMOs extend beyond infancy, with potential therapeutic applications in modulating immune responses, promoting epithelial health, and reducing inflammation in IBD. This review summarizes current research on the role of 2\u2032-FL in inflammation and colitis, exploring its potential role in treating IBD.<\/jats:p>","DOI":"10.1177\/17562848251386319","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:29:29Z","timestamp":1761740969000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Microbiota-targeted strategies in IBD: therapeutic promise of 2\u2032-fucosyllactose and beyond"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3174-317X","authenticated-orcid":false,"given":"Nicholas","family":"Fanous","sequence":"first","affiliation":[{"name":"St Vincent\u2019s Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2537-3092","authenticated-orcid":false,"given":"Nicholas J.","family":"Talley","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia"},{"name":"NHMRC Centre of Research Excellence in Transforming Gut Health, Hunter Medical Research Institute Building, New Lambton, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3408-7277","authenticated-orcid":false,"given":"Thanaboon","family":"Chaemsupaphan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Gastroenterology, Siriraj Hospital, Mahidol University, Bangkok, Thailand"},{"name":"Concord Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Lee","sequence":"additional","affiliation":[{"name":"Faculty of Health, Macquarie School of Medicine, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-8901","authenticated-orcid":false,"given":"Binod","family":"Rayamajhee","sequence":"additional","affiliation":[{"name":"School of Biological, Earth and Environmental Sciences, UNSW, Sydney, NSW, Australia"},{"name":"School of Optometry and Vision Science, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaghayegh","family":"Baradaran Ghavami","sequence":"additional","affiliation":[{"name":"Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Centre, Research Institute for Gastro-enterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesa","family":"Kazemifard","sequence":"additional","affiliation":[{"name":"Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Centre, Research Institute for Gastro-enterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Asadzadeh Aghdaei","sequence":"additional","affiliation":[{"name":"Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Centre, Research Institute for Gastro-enterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran"},{"name":"Orange Health Services, Orange, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Chuang","sequence":"additional","affiliation":[{"name":"Intrinsic Medicine, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5944-3488","authenticated-orcid":false,"given":"Rupert W.","family":"Leong","sequence":"additional","affiliation":[{"name":"Concord Hospital, Level 1 West, 1 Hospital Road, Sydney, NSW 2139, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7247238"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/nutrit\/nux044"},{"issue":"1","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12934-021-01599-y","article-title":"Gold standard for nutrition: a review of human milk oligosaccharide and its effects on infant gut microbiota","volume":"20","author":"Zhang S","year":"2021","unstructured":"Zhang S, Li T, Xie J, et al. Gold standard for nutrition: a review of human milk oligosaccharide and its effects on infant gut microbiota. Microb Cell Fact 2021; 20(1): 108.","journal-title":"Microb Cell Fact"},{"issue":"9","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.3390\/nu12092808","article-title":"Effects of human milk oligosaccharides on the adult gut microbiota and barrier function","volume":"12","author":"Suligoj T","year":"2020","unstructured":"Suligoj T, Vigsnaes LK, Abbeele PVD, et al. Effects of human milk oligosaccharides on the adult gut microbiota and barrier function. Nutrients 2020; 12(9): 2808.","journal-title":"Nutrients"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"1015890","DOI":"10.3389\/fcimb.2022.1015890","article-title":"Overrepresentation of Enterobacteriaceae and Escherichia coli is the major gut microbiome signature in Crohn\u2019s disease and ulcerative colitis; a comprehensive metagenomic analysis of IBDMDB datasets","volume":"12","author":"Khorsand B","year":"2022","unstructured":"Khorsand B, Asadzadeh Aghdaei H, Nazemalhosseini-Mojarad E, et al. Overrepresentation of Enterobacteriaceae and Escherichia coli is the major gut microbiome signature in Crohn\u2019s disease and ulcerative colitis; a comprehensive metagenomic analysis of IBDMDB datasets. Front Cell Infect Microbiol 2022; 12: 1015890.","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1017\/S0007114516003354","article-title":"Oral supplementation of healthy adults with 2\u2032-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota","volume":"116","author":"Elison E","year":"2016","unstructured":"Elison E, Vigsnaes LK, Rindom Krogsgaard L, et al. Oral supplementation of healthy adults with 2\u2032-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. Br J Nutr 2016; 116(8): 1356\u20131368.","journal-title":"Br J Nutr"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073464"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00277"},{"issue":"8","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1136\/gutjnl-2013-304833","article-title":"A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis","volume":"63","author":"Machiels K","year":"2014","unstructured":"Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014; 63(8): 1275\u20131283.","journal-title":"Gut"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.733992"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-023-03374-w"},{"issue":"7","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1128\/IAI.00425-15","article-title":"Enterococcus faecalis gelatinase mediates intestinal permeability via protease-activated receptor 2","volume":"83","author":"Maharshak N","year":"2015","unstructured":"Maharshak N, Huh EY, Paiboonrungruang C, et al. Enterococcus faecalis gelatinase mediates intestinal permeability via protease-activated receptor 2. Infect Immun 2015; 83(7): 2762\u20132770.","journal-title":"Infect Immun"},{"issue":"3","key":"e_1_3_4_14_2","article-title":"Goblet cells: guardians of gut immunity and their role in gastrointestinal diseases","volume":"2","author":"Tonetti FR","year":"2024","unstructured":"Tonetti FR, Eguileor A, Llorente C. Goblet cells: guardians of gut immunity and their role in gastrointestinal diseases. eGastroenterology 2024; 2(3): e100098.","journal-title":"eGastroenterology"},{"issue":"6","key":"e_1_3_4_15_2","article-title":"Advancements in inflammatory bowel disease: a narrative review of diagnostics, management, epidemiology, prevalence, patient outcomes, quality of life, and clinical presentation","volume":"15","author":"Muzammil MA","year":"2023","unstructured":"Muzammil MA, Fariha F, Patel T, et al. Advancements in inflammatory bowel disease: a narrative review of diagnostics, management, epidemiology, prevalence, patient outcomes, quality of life, and clinical presentation. Cureus 2023; 15(6): e41120.","journal-title":"Cureus"},{"issue":"8","key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5694\/mja2.50910","article-title":"High prevalence of Crohn disease and ulcerative colitis among older people in Sydney","volume":"214","author":"Pudipeddi A","year":"2021","unstructured":"Pudipeddi A, Liu J, Kariyawasam V, et al. High prevalence of Crohn disease and ulcerative colitis among older people in Sydney. Med J Aust 2021; 214(8): 365\u2013370.","journal-title":"Med J Aust"},{"issue":"2","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S2468-1253(21)00400-3","article-title":"Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Haifer C","year":"2022","unstructured":"Haifer C, Paramsothy S, Kaakoush NO, et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2022; 7(2): 141\u2013151.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327742"},{"key":"e_1_3_4_19_2","article-title":"Recent advances in the treatment of IBD: targets, mechanisms and related therapies","author":"Liu J","year":"2023","unstructured":"Liu J, Di B, Xu LL. Recent advances in the treatment of IBD: targets, mechanisms and related therapies. Cytokine Growth Factor Rev 2023; 71\u201372: 1\u201312.","journal-title":"Cytokine Growth Factor Rev"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad120"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-320260"},{"issue":"4","key":"e_1_3_4_22_2","article-title":"Fecal transplantation for treatment of inflammatory bowel disease","volume":"4","author":"Imdad A","year":"2023","unstructured":"Imdad A, Pandit NG, Zaman M, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2023; 4(4): CD012774.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2023.03.020"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00002"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061757"},{"issue":"2","key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.cgh.2018.09.017","article-title":"Microbiome 101: studying, analyzing, and interpreting gut microbiome data for clinicians","volume":"17","author":"Allaband C","year":"2019","unstructured":"Allaband C, McDonald D, Vazquez-Baeza Y, et al. Microbiome 101: studying, analyzing, and interpreting gut microbiome data for clinicians. Clin Gastroenterol Hepatol 2019; 17(2): 218\u2013230.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.3390\/ijms24043817","article-title":"Inflammatory bowel diseases and gut microbiota","volume":"24","author":"Haneishi Y","year":"2023","unstructured":"Haneishi Y, Furuya Y, Hasegawa M, et al. Inflammatory bowel diseases and gut microbiota. Int J Mol Sci 2023; 24(4): 3817.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.08.006"},{"key":"e_1_3_4_29_2","article-title":"Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges","volume":"12","author":"Paudel D","year":"2024","unstructured":"Paudel D, Nair DVT, Joseph G, et al. Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges. Gastroenterol Rep (Oxf) 2024; 12: goae033.","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12820"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306541"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00605-x"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"1292673","DOI":"10.3389\/fphys.2023.1292673","article-title":"A systematic review on the effects of exercise on gut microbial diversity, taxonomic composition, and microbial metabolites: identifying research gaps and future directions","volume":"14","author":"Cullen JMA","year":"2023","unstructured":"Cullen JMA, Shahzad S, Dhillon J. A systematic review on the effects of exercise on gut microbial diversity, taxonomic composition, and microbial metabolites: identifying research gaps and future directions. Front Physiol 2023; 14: 1292673.","journal-title":"Front Physiol"},{"issue":"1","key":"e_1_3_4_34_2","article-title":"A phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis","volume":"160","author":"Henn MR","year":"2021","unstructured":"Henn MR, O\u2019Brien EJ, Diao L, et al. A phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis. Gastroenterology 2021; 160(1): 115\u2013127.e30.","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_3_4_35_2","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial","volume":"149","author":"Moayyedi P","year":"2015","unstructured":"Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015; 149(1): 102\u2013109.e6.","journal-title":"Gastroenterology"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx063"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20046"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26196076"},{"issue":"11","key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.3390\/ijms25116022","article-title":"Effects of probiotics on gut microbiota: an overview","volume":"25","author":"Chandrasekaran P","year":"2024","unstructured":"Chandrasekaran P, Weiskirchen S, Weiskirchen R. Effects of probiotics on gut microbiota: an overview. Int J Mol Sci 2024; 25(11): 6022.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"1211271","DOI":"10.3389\/fmicb.2023.1211271","article-title":"Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022","volume":"14","author":"Huang C","year":"2023","unstructured":"Huang C, Hao W, Wang X, et al. Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022. Front Microbiol 2023; 14: 1211271.","journal-title":"Front Microbiol"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12636"},{"issue":"1","key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.MIB.0000437495.30052.be","article-title":"Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn\u2019s disease, and pouchitis: meta-analysis of randomized controlled trials","volume":"20","author":"Shen J","year":"2014","unstructured":"Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn\u2019s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 2014; 20(1): 21\u201335.","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crfs.2025.101061"},{"issue":"24","key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.3390\/nu16244337","article-title":"Diet and microbiota modulation for chronic pouchitis: evidence, challenges, and opportunities","volume":"16","author":"Puca P","year":"2024","unstructured":"Puca P, Del Gaudio A, Becherucci G, et al. Diet and microbiota modulation for chronic pouchitis: evidence, challenges, and opportunities. Nutrients 2024; 16(24): 4337.","journal-title":"Nutrients"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.10.015"},{"issue":"2","key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.12938\/bmfh.2015-017","article-title":"Perioperative supplementation with bifidobacteria improves postoperative nutritional recovery, inflammatory response, and fecal microbiota in patients undergoing colorectal surgery: a prospective, randomized clinical trial","volume":"35","author":"Mizuta M","year":"2016","unstructured":"Mizuta M, Endo I, Yamamoto S, et al. Perioperative supplementation with bifidobacteria improves postoperative nutritional recovery, inflammatory response, and fecal microbiota in patients undergoing colorectal surgery: a prospective, randomized clinical trial. Biosci Microbiota Food Health 2016; 35(2): 77\u201387.","journal-title":"Biosci Microbiota Food Health"},{"issue":"1","key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2329-8901.1000163","article-title":"Influence of Lactobacillus and Bifidobacterium combination on the gut microbiota, clinical course, and local gut inflammation in patients with ulcerative colitis: a preliminary, single-center, open-label study","volume":"5","author":"Pilarczyk-Zurek M","year":"2017","unstructured":"Pilarczyk-Zurek M, Zwolinska-Wcislo M, Mach T, et al. Influence of Lactobacillus and Bifidobacterium combination on the gut microbiota, clinical course, and local gut inflammation in patients with ulcerative colitis: a preliminary, single-center, open-label study. J Probiotics Health 2017; 5(1): 1\u20136.","journal-title":"J Probiotics Health"},{"issue":"16","key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.3390\/jcm13164622","article-title":"The microbiome in inflammatory bowel disease","volume":"13","author":"Jauregui-Amezaga A","year":"2024","unstructured":"Jauregui-Amezaga A, Smet A. The microbiome in inflammatory bowel disease. J Clin Med 2024; 13(16): 4622.","journal-title":"J Clin Med"},{"issue":"4","key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/apt.14203","article-title":"Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease","volume":"46","author":"Derwa Y","year":"2017","unstructured":"Derwa Y, Gracie DJ, Hamlin PJ, et al. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2017; 46(4): 389\u2013400.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00284-023-03526-3","article-title":"Quality management of probiotics: ensuring safety and maximizing health benefits","volume":"81","author":"Ahire JJ","year":"2023","unstructured":"Ahire JJ, Rohilla A, Kumar V, et al. Quality management of probiotics: ensuring safety and maximizing health benefits. Curr Microbiol 2023; 81(1): 1.","journal-title":"Curr Microbiol"},{"issue":"10","key":"e_1_3_4_51_2","article-title":"S240 Probiotics Counterfeit! Study finds most labels mislead customers","volume":"118","author":"Hazan S","year":"2023","unstructured":"Hazan S, Papousis A. S240 Probiotics Counterfeit! Study finds most labels mislead customers. Am J Gastroenterol 2023; 118(10S): S179\u2013S180.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"e_1_3_4_52_2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1053\/j.gastro.2019.01.022","article-title":"Insights into how probiotics colonize the healthy human gut","volume":"156","author":"Ferreiro A","year":"2019","unstructured":"Ferreiro A, Dantas G, Ciorba MA. Insights into how probiotics colonize the healthy human gut. Gastroenterology 2019; 156(3): 820\u2013822.","journal-title":"Gastroenterology"},{"key":"e_1_3_4_53_2","doi-asserted-by":"crossref","first-page":"1000517","DOI":"10.3389\/fnut.2022.1000517","article-title":"The promotion mechanism of prebiotics for probiotics: a review","volume":"9","author":"You S","year":"2022","unstructured":"You S, Ma Y, Yan B, et al. The promotion mechanism of prebiotics for probiotics: a review. Front Nutr 2022; 9: 1000517.","journal-title":"Front Nutr"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2022.02.044"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nutos.2024.09.004"},{"issue":"5","key":"e_1_3_4_56_2","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/ibd\/izae115","article-title":"Prebiotics for induction and maintenance of remission in inflammatory bowel disease: systematic review and meta-analysis","volume":"31","author":"Limketkai BN","year":"2025","unstructured":"Limketkai BN, Godoy-Brewer G, Shah ND, et al. Prebiotics for induction and maintenance of remission in inflammatory bowel disease: systematic review and meta-analysis. Inflamm Bowel Dis 2025; 31(5): 1220\u20131230.","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2023.11.007"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodres.2020.109473"},{"key":"e_1_3_4_59_2","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ijbiomac.2020.10.259","article-title":"Scutellaria baicalensis Georgi polysaccharide ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota","volume":"166","author":"Cui L","year":"2021","unstructured":"Cui L, Guan X, Ding W, et al. Scutellaria baicalensis Georgi polysaccharide ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota. Int J Biol Macromol 2021; 166: 1035\u20131045.","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"e_1_3_4_60_2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00394-015-0962-6","article-title":"Fructooligosaccharides exert intestinal anti-inflammatory activity in the CD4+ CD62L+ T cell transfer model of colitis in C57BL\/6J mice","volume":"55","author":"Capitan-Canadas F","year":"2016","unstructured":"Capitan-Canadas F, Ocon B, Aranda CJ, et al. Fructooligosaccharides exert intestinal anti-inflammatory activity in the CD4+ CD62L+ T cell transfer model of colitis in C57BL\/6J mice. Eur J Nutr 2016; 55(4): 1445\u20131454.","journal-title":"Eur J Nutr"},{"issue":"3","key":"e_1_3_4_61_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10096-019-03721-w","article-title":"The effects of inulin on gut microbial composition: a systematic review of evidence from human studies","volume":"39","author":"Le Bastard Q","year":"2020","unstructured":"Le Bastard Q, Chapelet G, Javaudin F, et al. The effects of inulin on gut microbial composition: a systematic review of evidence from human studies. Eur J Clin Microbiol Infect Dis 2020; 39(3): 403\u2013413.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"8","key":"e_1_3_4_62_2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3390\/nu10081038","article-title":"Human milk oligosaccharides and immune system development","volume":"10","author":"Plaza-Diaz J","year":"2018","unstructured":"Plaza-Diaz J, Fontana L, Gil A. Human milk oligosaccharides and immune system development. Nutrients 2018; 10(8): 1038.","journal-title":"Nutrients"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2012.09.001"},{"key":"e_1_3_4_64_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/bs.accb.2015.08.002","article-title":"Human milk oligosaccharides (HMOS): structure, function, and enzyme-catalyzed synthesis","volume":"72","author":"Chen X.","year":"2015","unstructured":"Chen X. Human milk oligosaccharides (HMOS): structure, function, and enzyme-catalyzed synthesis. Adv Carbohydr Chem Biochem 2015; 72: 113\u2013190.","journal-title":"Adv Carbohydr Chem Biochem"},{"key":"e_1_3_4_65_2","doi-asserted-by":"crossref","first-page":"574459","DOI":"10.3389\/fnut.2020.574459","article-title":"Time of lactation and maternal fucosyltransferase genetic polymorphisms determine the variability in human milk oligosaccharides","volume":"7","author":"Lefebvre G","year":"2020","unstructured":"Lefebvre G, Shevlyakova M, Charpagne A, et al. Time of lactation and maternal fucosyltransferase genetic polymorphisms determine the variability in human milk oligosaccharides. Front Nutr 2020; 7: 574459.","journal-title":"Front Nutr"},{"key":"e_1_3_4_66_2","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3389\/fimmu.2019.01773","article-title":"Immunomodulatory and prebiotic effects of 2\u2032-fucosyllactose in suckling rats","volume":"10","author":"Azagra-Boronat I","year":"2019","unstructured":"Azagra-Boronat I, Massot-Cladera M, Mayneris-Perxachs J, et al. Immunomodulatory and prebiotic effects of 2\u2032-fucosyllactose in suckling rats. Front Immunol 2019; 10: 1773.","journal-title":"Front Immunol"},{"key":"e_1_3_4_67_2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3389\/fmicb.2019.01385","article-title":"Alleviation of intestinal inflammation by oral supplementation with 2-fucosyllactose in mice","volume":"10","author":"Grabinger T","year":"2019","unstructured":"Grabinger T, Glaus Garzon JF, Hausmann M, et al. Alleviation of intestinal inflammation by oral supplementation with 2-fucosyllactose in mice. Front Microbiol 2019; 10: 1385.","journal-title":"Front Microbiol"},{"issue":"7","key":"e_1_3_4_68_2","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.3168\/jds.2024-24325","article-title":"Ameliorating effect of 2\u2032-fucosyllactose and 6\u2032-sialyllactose on lipopolysaccharide-induced intestinal inflammation","volume":"107","author":"Kim JY","year":"2024","unstructured":"Kim JY, Lee S, Kim G, et al. Ameliorating effect of 2\u2032-fucosyllactose and 6\u2032-sialyllactose on lipopolysaccharide-induced intestinal inflammation. J Dairy Sci 2024; 107(7): 4147\u20134160.","journal-title":"J Dairy Sci"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fbio.2024.104162"},{"issue":"5","key":"e_1_3_4_70_2","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.26599\/FSHW.2022.9250205","article-title":"2\u2032-Fucosyllactose alleviate immune checkpoint blockade-associated colitis by reshaping gut microbiota and activating AHR pathway","volume":"13","author":"Yan S","year":"2024","unstructured":"Yan S, Yu L, Tian F, et al. 2\u2032-Fucosyllactose alleviate immune checkpoint blockade-associated colitis by reshaping gut microbiota and activating AHR pathway. Food Sci Hum Wellness 2024; 13(5): 2543\u20132561.","journal-title":"Food Sci Hum Wellness"},{"issue":"4","key":"e_1_3_4_71_2","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00298-24","article-title":"A human milk oligosaccharide prevents intestinal inflammation in adulthood via modulating gut microbial metabolism","volume":"15","author":"Schalich KM","year":"2024","unstructured":"Schalich KM, Buendia MA, Kaur H, et al. A human milk oligosaccharide prevents intestinal inflammation in adulthood via modulating gut microbial metabolism. mBio 2024; 15(4): e0029824.","journal-title":"mBio"},{"issue":"1","key":"e_1_3_4_72_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/foods12010186","article-title":"The milk active ingredient, 2\u2032-fucosyllactose, inhibits inflammation and promotes MUC2 secretion in LS174T goblet cells in vitro","volume":"12","author":"Yao Q","year":"2023","unstructured":"Yao Q, Li H, Gao Y, et al. The milk active ingredient, 2\u2032-fucosyllactose, inhibits inflammation and promotes MUC2 secretion in LS174T goblet cells in vitro. Foods 2023; 12(1): 186.","journal-title":"Foods"},{"issue":"1","key":"e_1_3_4_73_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41390-020-0852-3","article-title":"The human milk oligosaccharides 2\u2032-fucosyllactose and 6\u2032-sialyllactose protect against the development of necrotizing enterocolitis by inhibiting toll-like receptor 4 signaling","volume":"89","author":"Sodhi CP","year":"2021","unstructured":"Sodhi CP, Wipf P, Yamaguchi Y, et al. The human milk oligosaccharides 2\u2032-fucosyllactose and 6\u2032-sialyllactose protect against the development of necrotizing enterocolitis by inhibiting toll-like receptor 4 signaling. Pediatr Res 2021; 89(1): 91\u2013101.","journal-title":"Pediatr Res"},{"key":"e_1_3_4_74_2","doi-asserted-by":"crossref","first-page":"822020","DOI":"10.3389\/fnut.2022.822020","article-title":"2\u2032-Fucosyllactose ameliorates inflammatory bowel disease by modulating gut microbiota and promoting MUC2 expression","volume":"9","author":"Yao Q","year":"2022","unstructured":"Yao Q, Fan L, Zheng N, et al. 2\u2032-Fucosyllactose ameliorates inflammatory bowel disease by modulating gut microbiota and promoting MUC2 expression. Front Nutr 2022; 9: 822020.","journal-title":"Front Nutr"},{"key":"e_1_3_4_75_2","doi-asserted-by":"crossref","first-page":"106659","DOI":"10.1016\/j.intimp.2020.106659","article-title":"2\u2032-Fucosyllactose inhibits imiquimod-induced psoriasis in mice by regulating Th17 cell response via the STAT3 signaling pathway","volume":"85","author":"Lei K","year":"2020","unstructured":"Lei K, Wang D, Lin L, et al. 2\u2032-Fucosyllactose inhibits imiquimod-induced psoriasis in mice by regulating Th17 cell response via the STAT3 signaling pathway. Int Immunopharmacol 2020; 85: 106659.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"e_1_3_4_76_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/foods11020151","article-title":"2\u2032-Fucosyllactose ameliorates oxidative stress damage in d-galactose-induced aging mice by regulating gut microbiota and AMPK\/SIRT1\/FOXO1 pathway","volume":"11","author":"Wang J","year":"2022","unstructured":"Wang J, Hu JQ, Song YJ, et al. 2\u2032-Fucosyllactose ameliorates oxidative stress damage in d-galactose-induced aging mice by regulating gut microbiota and AMPK\/SIRT1\/FOXO1 pathway. Foods 2022; 11(2): 151.","journal-title":"Foods"},{"issue":"5","key":"e_1_3_4_77_2","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201900976","article-title":"Human milk oligosaccharides differently modulate goblet cells under homeostatic, proinflammatory conditions and ER stress","volume":"64","author":"Cheng L","year":"2020","unstructured":"Cheng L, Kong C, Walvoort MTC, et al. Human milk oligosaccharides differently modulate goblet cells under homeostatic, proinflammatory conditions and ER stress. Mol Nutr Food Res 2020; 64(5): e1900976.","journal-title":"Mol Nutr Food Res"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2021.09.015"},{"issue":"10","key":"e_1_3_4_79_2","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3945\/jn.116.230706","article-title":"The human milk oligosaccharide 2\u2032-Fucosyllactose quenches Campylobacter jejuni-induced inflammation in human epithelial cells HEp-2 and HT-29 and in mouse intestinal mucosa","volume":"146","author":"Yu ZT","year":"2016","unstructured":"Yu ZT, Nanthakumar NN, Newburg DS. The human milk oligosaccharide 2\u2032-Fucosyllactose quenches Campylobacter jejuni-induced inflammation in human epithelial cells HEp-2 and HT-29 and in mouse intestinal mucosa. J Nutr 2016; 146(10): 1980\u20131990.","journal-title":"J Nutr"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307544"},{"issue":"5","key":"e_1_3_4_81_2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3390\/nu12051284","article-title":"The protective effects of 2\u2032-fucosyllactose against E. Coli O157 infection are mediated by the regulation of gut microbiota and the inhibition of pathogen adhesion","volume":"12","author":"Wang Y","year":"2020","unstructured":"Wang Y, Zou Y, Wang J, et al. The protective effects of 2\u2032-fucosyllactose against E. Coli O157 infection are mediated by the regulation of gut microbiota and the inhibition of pathogen adhesion. Nutrients 2020; 12(5): 1284.","journal-title":"Nutrients"},{"issue":"6","key":"e_1_3_4_82_2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41429-019-0151-6","article-title":"1-Amino-2\u2032-fucosyllactose inhibits biofilm formation by","volume":"72","author":"Craft KM","year":"2019","unstructured":"Craft KM, Townsend SD. 1-Amino-2\u2032-fucosyllactose inhibits biofilm formation by Streptococcus agalactiae. J Antibiot (Tokyo) 2019; 72(6): 507\u2013512.","journal-title":"Streptococcus agalactiae. J Antibiot (Tokyo)"},{"issue":"1","key":"e_1_3_4_83_2","article-title":"CD11B\/CD18 Sialylation regulates neutrophil trafficking and inflammatory function in the intestine","volume":"30","author":"Brazil J","year":"2024","unstructured":"Brazil J, Azcutia V, Kelm M, et al. CD11B\/CD18 Sialylation regulates neutrophil trafficking and inflammatory function in the intestine. Inflamm Bowel Dis 2024; 30(1): S65.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"e_1_3_4_84_2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/microorganisms12020252","article-title":"Sialyllactose enhances the short-chain fatty acid production and barrier function of gut epithelial cells via nonbifidogenic modification of the fecal microbiome in human adults","volume":"12","author":"Sato Y","year":"2024","unstructured":"Sato Y, Kanayama M, Nakajima S, et al. Sialyllactose enhances the short-chain fatty acid production and barrier function of gut epithelial cells via nonbifidogenic modification of the fecal microbiome in human adults. Microorganisms 2024; 12(2): 252.","journal-title":"Microorganisms"},{"key":"e_1_3_4_85_2","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.crfs.2024.100851","article-title":"The effect of nerve cells on the intestinal barrier function and the influence of human milk oligosaccharides (hMOs) on the intestinal neuro-epithelial crosstalk","volume":"9","author":"Chen X","year":"2024","unstructured":"Chen X, Gasaly N, Tang X, et al. The effect of nerve cells on the intestinal barrier function and the influence of human milk oligosaccharides (hMOs) on the intestinal neuro-epithelial crosstalk. Curr Res Food Sci 2024; 9: 100851.","journal-title":"Curr Res Food Sci"},{"issue":"2","key":"e_1_3_4_86_2","doi-asserted-by":"crossref","DOI":"10.1093\/jambio\/lxae034","article-title":"Comparison of prebiotic candidates in ulcerative colitis using an in vitro fermentation model","volume":"135","author":"Kennedy JM","year":"2024","unstructured":"Kennedy JM, De Silva A, Walton GE, et al. Comparison of prebiotic candidates in ulcerative colitis using an in vitro fermentation model. J Appl Microbiol 2024; 135(2): lxae034.","journal-title":"J Appl Microbiol"},{"issue":"3","key":"e_1_3_4_87_2","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/nu13030938","article-title":"Impact of 2\u2032-Fucosyllactose on gut microbiota composition in adults with chronic gastrointestinal conditions: batch culture fermentation model and pilot clinical trial findings","volume":"13","author":"Ryan JJ","year":"2021","unstructured":"Ryan JJ, Monteagudo-Mera A, Contractor N, et al. Impact of 2\u2032-Fucosyllactose on gut microbiota composition in adults with chronic gastrointestinal conditions: batch culture fermentation model and pilot clinical trial findings. Nutrients 2021; 13(3): 938.","journal-title":"Nutrients"},{"issue":"10","key":"e_1_3_4_88_2","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3390\/microorganisms12101977","article-title":"Bifidogenic effect of human milk oligosaccharides on pediatric IBD fecal microbiota","volume":"12","author":"Otaru N","year":"2024","unstructured":"Otaru N, Bajic D, Van den Abbeele P, et al. Bifidogenic effect of human milk oligosaccharides on pediatric IBD fecal microbiota. Microorganisms 2024; 12(10): 1977.","journal-title":"Microorganisms"},{"issue":"5","key":"e_1_3_4_89_2","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ajcnut.2023.08.016","article-title":"Inulin-type fructans and 2\u2032-fucosyllactose alter both microbial composition and appear to alleviate stress-induced mood state in a working population compared to placebo (maltodextrin): the EFFICAD trial, a randomized, controlled trial","volume":"118","author":"Jackson PP","year":"2023","unstructured":"Jackson PP, Wijeyesekera A, Williams CM, et al. Inulin-type fructans and 2\u2032-fucosyllactose alter both microbial composition and appear to alleviate stress-induced mood state in a working population compared to placebo (maltodextrin): the EFFICAD trial, a randomized, controlled trial. Am J Clin Nutr 2023; 118(5): 938\u2013955.","journal-title":"Am J Clin Nutr"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.3945\/jn.116.236919"},{"issue":"2","key":"e_1_3_4_91_2","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03196-19","article-title":"Linking human milk oligosaccharides, infant fecal community types, and later risk to require antibiotics","volume":"11","author":"Berger B","year":"2020","unstructured":"Berger B, Porta N, Foata F, et al. Linking human milk oligosaccharides, infant fecal community types, and later risk to require antibiotics. mBio 2020; 11(2): e03196-19.","journal-title":"mBio"},{"issue":"14","key":"e_1_3_4_92_2","doi-asserted-by":"crossref","first-page":"11422","DOI":"10.3390\/ijms241411422","article-title":"An extensively hydrolyzed formula supplemented with two human milk oligosaccharides modifies the fecal microbiome and metabolome in infants with cow\u2019s milk protein allergy","volume":"24","author":"Boulange CL","year":"2023","unstructured":"Boulange CL, Pedersen HK, Martin FP, et al. An extensively hydrolyzed formula supplemented with two human milk oligosaccharides modifies the fecal microbiome and metabolome in infants with cow\u2019s milk protein allergy. Int J Mol Sci 2023; 24(14): 11422.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_4_93_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.12.040","article-title":"Administration of human milk oligosaccharide (2\u2032-fucosyllactose) reduces dysbiosis and increases short chain fatty acids in children and young adults following HSCT: a prospective, single-center study","volume":"30","author":"Ramos KN","year":"2024","unstructured":"Ramos KN, Lake KE, Hoerth C, et al. Administration of human milk oligosaccharide (2\u2032-fucosyllactose) reduces dysbiosis and increases short chain fatty acids in children and young adults following HSCT: a prospective, single-center study. Transplant Cell Ther 2024; 30(2, Suppl.): S16.","journal-title":"Transplant Cell Ther"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.05.049"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad289"},{"issue":"1","key":"e_1_3_4_96_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12916-025-04016-y","article-title":"Gut virome and its implications in the pathogenesis and therapeutics of inflammatory bowel disease","volume":"23","author":"Wu Y","year":"2025","unstructured":"Wu Y, Cheng R, Lin H, et al. Gut virome and its implications in the pathogenesis and therapeutics of inflammatory bowel disease. BMC Med 2025; 23(1): 183.","journal-title":"BMC Med"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251386319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848251386319","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251386319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T01:13:51Z","timestamp":1762132431000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848251386319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":95,"alternative-id":["10.1177\/17562848251386319"],"URL":"https:\/\/doi.org\/10.1177\/17562848251386319","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"17562848251386319"}}